Grünenthal is a global leader in pain management.
Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. We are focusing all of our activities and efforts on moving towards our vision of a World Free of Pain.
Commercial presence
28
We are present in 28 countries with affiliates in Europe, Latin America, and the US.
Market presence
100
Our products are sold in around 100 countries.
Strong and capable team
4,300
4,300 employees work for our group worldwide.
What we do
As a fully integrated research & development company we bring innovative pain treatments and state-of-the-art technologies to patients.
Learn more about us
Annual Report 2024/25
Grünenthal has a clear, bold vision: a World Free of Pain. In 2024, we took big steps forward in developing innovative medicines for patients living with pain worldwide. The latest Grünenthal Report provides information about our key objectives and activities, as well as our recent business development highlights and financial performance.
Responsibility Report 2023
Grünenthal’s strategy and culture are closely tied to its deep commitment to conducting business responsibly. We aim to have a net-positive impact on patients, employees, partners, and wider society. Each year, we publish our progress in a detailed and externally audited report – in line with the Global Reporting Initiative (GRI) standards.
Check out our latest Responsibility Report.
Pioneering thinkers
Our passion is innovation. We are driven to seek new solutions for patients with severe diseases and high unmet medical needs – and make these solutions accessible to patients.
Find out more
Careers
Ready to create a brighter future for our patients? With us, let your passion and ideas flow and drive innovation to improve our patients’ lives.
Join forces.
Make an impact.
Innovate for a world free of pain.
Work with Grünenthal
M-N/A-UK-03-25-0003 March 2025